The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems
Open accessAbstract
BACKGROUND: Prokaryotes have evolved multiple systems to combat invaders such as viruses and plasmids. Examples of such defense systems include receptor masking, restriction-modification (R-M) systems, DNA interference (Argonaute), bacteriophage exclusion (BREX or PGL), and abortive infection, all of which act in an innate, nonspecific manner. In addition, prokaryotes have evolved adaptive, heritable immune systems: clustered regularly interspaced palindromic repeats (CRISPR) and the CRISPR-associated proteins (CRISPR-Cas). Adaptive immunity is conferred by the integration of DNA sequences from an invading element into the CRISPR array (adaptation), which is transcribed into long pre-CRISPR RNAs (pre-crRNAs) and processed into short crRNAs (expression), which guide Cas proteins to specifically degrade the cognate DNA on subsequent exposures (interference). ADVANCES: A plethora of distinct CRISPR-Cas systems are represented in genomes of most archaea and almost half of the bacteria. The latest CRISPR-Cas classification scheme delineates two classes that are each subdivided into three types. Integration of biochemistry and molecular genetics has contributed substantially to revealing many of the unique features of the variant CRISPR-Cas types. Additionally, structural analysis and single-molecule studies have further advanced our understanding of the molecular basis of CRISPR-Cas functionality. Recent progress includes relevant steps in the adaptation stage, when fragments of foreign DNA are processed and incorporated as new spacers into the CRISPR array. In addition, three novel CRISPR-Cas types (IV, V, and VI) have been identified, and in particular, the type V interference complexes have been experimentally characterized. Moreover, the ability to easily program sequence-specific DNA targeting and cleavage by CRISPR-Cas components, as demonstrated for Cas9 and Cpf1, allows for the application of CRISPR-Cas components as highly effective tools for genetic engineering and gene regulation in a wide range of eukaryotes and prokaryotes. The pressing issue of off-target cleavage by the Cas9 nuclease is being actively addressed using structure-guided engineering. OUTLOOK: Although our understanding of the CRISPR-Cas system has increased tremendously over the past few years, much remains to be revealed. The continuing discovery of CRISPR-Cas variants will provide direct tests of the recently proposed modular scenario for the evolution of CRISPR-Cas systems. The recent discovery and characterization of new CRISPR-Cas types with previously unknown features implies that our current knowledge has relatively limited power for predicting the functional details of distantly related CRISPR-Cas variants. Hence, newly discovered CRISPR-Cas systems need to be dissected thoroughly to gain insight into their biological roles, to unravel their molecular mechanisms, and to harness their potential for biotechnology. Key outstanding questions regarding CRISPR-Cas biology include the ecological roles of microbial adaptive immunity, the high rates of CRISPR-Cas horizontal transfer, and the coevolution of CRISPR-Cas and phage-encoded anti-CRISPR proteins. Relatively little is known about the regulation of CRISPR-Cas expression, and about the roles of CRISPR-Cas in processes other than defense. With respect to the CRISPR-Cas mechanism, details illuminating the connection between the adaptation stage and the interference stage in primed spacer acquisition remain elusive. A key aspect of CRISPR-Cas that is poorly understood at present is self/nonself discrimination. The discrimination mechanisms seem to differ substantially among CRISPR variants. Recent comparison of class 2 type effector complexes (Cas9/Cpf1) has revealed overall architectural similarities as well as structural and mechanistic differences, as had previously been found for the distinct types of class 1 effector complexes (Cascade/Cmr). These variations may translate into complementary biotechnological applications. As well as innovative tools for basic research, CRISPR-associated effector complexes will be instrumental for developing the next generation of antiviral prophylactics and therapeutics. For applications in human gene therapy, improved methods for efficient and safe delivery of Cas9/Cpf1 and their guide RNAs to cells and tissues are still needed. Further insight into the basic details of CRISPR-Cas structure, functions, and biology—and characterization of new Cas effector proteins in particular—is crucial for optimizing and further expanding the diverse applications of CRISPR-Cas systems. Evolution of CRISPR-Cas systems resulted in incredible structural and functional diversity.: Class 1 CRISPR-Cas systems are considered to be the evolutionary ancestral systems. The class 2 systems have evolved from class 1 systems via the insertion of transposable elements encoding various nucleases, and are now being used as tools for genome editing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationRepurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016 · cited 1×
“The dCas9 has been used for transcriptional activation and repression [134-137], for localizing fluorescent protein labels [138], and for recruiting histone modifying enzymes [139, 140].”
MethodCpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Self-citationCRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · cited 1×
“The dCas9 has been used for transcriptional activation and repression [134-137], for localizing fluorescent protein labels [138], and for recruiting histone modifying enzymes [139, 140].”
MethodDouble nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants
Makarova, K. S., Wolf, Y. I., Iranzo, J., Shmakov, S. A., Alkhnbashi, O. S., Brouns, S. J. J., Charpentier, E., Cheng, D., Haft, D. H., Horvath, P., et al. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0299-x · Cited by 2,445
Self-citationDiversity, classification and evolution of CRISPR-Cas systems
Koonin, E. V., Makarova, K. S., & Zhang, F. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.008 · Cited by 1,423
Self-citationThe Biology of CRISPR-Cas: Backward and Forward
Hille, F., Richter, H., Wong, S. P., Bratovič, M., Ressel, S., & Charpentier, E. (2018) · Cell · doi:10.1016/j.cell.2017.11.032 · Cited by 1,039
Diversity and evolution of class 2 CRISPR–Cas systems
Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.184 · Cited by 1,029
Self-citationRNA-guided DNA insertion with CRISPR-associated transposases
Strecker, J., Ladha, A., Gardner, Z., Schmid-Burgk, J. L., Makarova, K. S., Koonin, E. V., & Zhang, F. (2019) · Science · doi:10.1126/science.aax9181 · Cited by 708
Self-citationStructural Basis for Guide RNA Processing and Seed-Dependent DNA Targeting by CRISPR-Cas12a
Swarts, D. C., van der Oost, J., & Jinek, M. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.03.016 · Cited by 608
Self-citationSmargon, A. A., Cox, D. B. T., Pyzocha, N. K., Zheng, K., Slaymaker, I. M., Gootenberg, J. S., Abudayyeh, O. A., Essletzbichler, P., Shmakov, S., Makarova, K. S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.023 · Cited by 575
Self-citationMechanistic Insights into the cis- and trans-Acting DNase Activities of Cas12a
Swarts, D. C., & Jinek, M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.021 · Cited by 592
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
Ishino, Y., Krupovic, M., & Forterre, P. (2018) · Journal of Bacteriology · doi:10.1128/jb.00580-17 · Cited by 558
Origins and evolution of CRISPR-Cas systems
Koonin, E. V., & Makarova, K. S. (2019) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2018.0087 · Cited by 494
Self-citationType III CRISPR–Cas systems produce cyclic oligoadenylate second messengers
Niewoehner, O., Garcia-Doval, C., Rostøl, J. T., Berk, C., Schwede, F., Bigler, L., Hall, J., Marraffini, L. A., & Jinek, M. (2017) · Nature · doi:10.1038/nature23467 · Cited by 509
Yan, W. X., Chong, S., Zhang, H., Makarova, K. S., Koonin, E. V., Cheng, D. R., & Scott, D. A. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.02.028 · Cited by 462
Self-citationAm I ready for CRISPR? A user's guide to genetic screens
Doench, J. G. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.97 · Cited by 452
Anti-CRISPR: discovery, mechanism and function
Pawluk, A., Davidson, A. R., & Maxwell, K. L. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.120 · Cited by 401
CRISPR-Cas: Adapting to change
Jackson, S. A., McKenzie, R. E., Fagerlund, R. D., Kieper, S. N., Fineran, P. C., & Brouns, S. J. J. (2017) · Science · doi:10.1126/science.aal5056 · Cited by 394
Karvelis, T., Bigelyte, G., Young, J. K., Hou, Z., Zedaveinyte, R., Budre, K., Paulraj, S., Djukanovic, V., Gasior, S., Silanskas, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa208 · Cited by 349
Evolutionary Genomics of Defense Systems in Archaea and Bacteria
Koonin, E. V., Makarova, K. S., & Wolf, Y. I. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090816-093830 · Cited by 348
Self-citationMolecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR–Cas Systems
O'Connell, M. R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.029 · Cited by 346
Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1
Yamano, T., Zetsche, B., Ishitani, R., Zhang, F., Nishimasu, H., & Nureki, O. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.035 · Cited by 322
Self-citationA decade of discovery: CRISPR functions and applications
Barrangou, R., & Horvath, P. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.92 · Cited by 319
CRISPRCasTyper: Automated Identification, Annotation, and Classification of CRISPR-Cas Loci
Russel, J., Pinilla-Redondo, R., Mayo-Muñoz, D., Shah, S. A., & Sørensen, S. J. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0059 · Cited by 307
RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes
East-Seletsky, A., O’Connell, M. R., Burstein, D., Knott, G. J., & Doudna, J. A. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.008 · Cited by 296
A conformational checkpoint between DNA binding and cleavage by CRISPR-Cas9
Dagdas, Y. S., Chen, J. S., Sternberg, S. H., Doudna, J. A., & Yildiz, A. (2017) · Science Advances · doi:10.1126/sciadv.aao0027 · Cited by 293
Recruitment of CRISPR-Cas systems by Tn7-like transposons
Peters, J. E., Makarova, K. S., Shmakov, S., & Koonin, E. V. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1709035114 · Cited by 292
Self-citationExpansion of the global RNA virome reveals diverse clades of bacteriophages
Neri, U., Wolf, Y. I., Roux, S., Camargo, A. P., Lee, B., Kazlauskas, D., Chen, I. M., Ivanova, N., Zeigler Allen, L., Paez-Espino, D., et al. (2022) · Cell · doi:10.1016/j.cell.2022.08.023 · Cited by 286
Self-citationRole of Recombinant DNA Technology to Improve Life
Khan, S., Ullah, M. W., Siddique, R., Nabi, G., Manan, S., Yousaf, M., & Hou, H. (2016) · International Journal of Genomics · doi:10.1155/2016/2405954 · Cited by 279
CRISPR–Cas in mobile genetic elements: counter-defence and beyond
Faure, G., Shmakov, S. A., Yan, W. X., Cheng, D. R., Scott, D. A., Peters, J. E., Makarova, K. S., & Koonin, E. V. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0204-7 · Cited by 271
Self-citationCas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editing
Swarts, D. C., & Jinek, M. (2018) · WIREs RNA · doi:10.1002/wrna.1481 · Cited by 267
Molecular mechanisms of CRISPR–Cas spacer acquisition
McGinn, J., & Marraffini, L. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0071-7 · Cited by 262
Repurposing CRISPR-Cas12b for mammalian genome engineering
Teng, F., Cui, T., Feng, G., Guo, L., Xu, K., Gao, Q., Li, T., Li, J., Zhou, Q., & Li, W. (2018) · Cell Discovery · doi:10.1038/s41421-018-0069-3 · Cited by 261
Structure of the Cpf1 endonuclease R-loop complex after target DNA cleavage
Stella, S., Alcón, P., & Montoya, G. (2017) · Nature · doi:10.1038/nature22398 · Cited by 244
Xiao, Y., Luo, M., Hayes, R. P., Kim, J., Ng, S., Ding, F., Liao, M., & Ke, A. (2017) · Cell · doi:10.1016/j.cell.2017.06.012 · Cited by 208
CRISPR-Cas3 induces broad and unidirectional genome editing in human cells
Morisaka, H., Yoshimi, K., Okuzaki, Y., Gee, P., Kunihiro, Y., Sonpho, E., Xu, H., Sasakawa, N., Naito, Y., Nakada, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13226-x · Cited by 198
Application of different types of CRISPR/Cas-based systems in bacteria
Liu, Z., Dong, H., Cui, Y., Cong, L., & Zhang, D. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01431-z · Cited by 185
Mobile Genetic Elements and Evolution of CRISPR-Cas Systems: All the Way There and Back
Koonin, E. V., & Makarova, K. S. (2017) · Genome Biology and Evolution · doi:10.1093/gbe/evx192 · Cited by 176
Self-citationShmakov, S. A., Makarova, K. S., Wolf, Y. I., Severinov, K. V., & Koonin, E. V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803440115 · Cited by 169
Self-citationThe application of the CRISPR-Cas system in antibiotic resistance
Tao, S., Chen, H., Li, N., & Liang, W. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s370869 · Cited by 147
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Advances in CRISPR-Cas systems for RNA targeting, tracking and editing
Wang, F., Wang, L., Zou, X., Duan, S., Li, Z., Deng, Z., Luo, J., Lee, S. Y., & Chen, S. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.03.016 · Cited by 128
Structural basis for the altered PAM recognition by engineered CRISPR-Cpf1
Nishimasu, H., Yamano, T., Gao, L., Zhang, F., Ishitani, R., & Nureki, O. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.019 · Cited by 102
Csx28 is a membrane pore that enhances CRISPR-Cas13b–dependent antiphage defense
VanderWal, A. R., Park, J.-U., Polevoda, B., Nicosia, J. K., Molina Vargas, A. M., Kellogg, E. H., & O’Connell, M. R. (2023) · Science · doi:10.1126/science.abm1184 · Cited by 55
The double life of CRISPR–Cas13
Bot, J. F., van der Oost, J., & Geijsen, N. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102789 · Cited by 50
Wörle, E., Newman, A., D’Silva, J., Burgio, G., & Grohmann, D. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac767 · Cited by 32
RNA targeting and cleavage by the type III-Dv CRISPR effector complex
Schwartz, E. A., Bravo, J. P. K., Ahsan, M., Macias, L. A., McCafferty, C. L., Dangerfield, T. L., Walker, J. N., Brodbelt, J. S., Palermo, G., Fineran, P. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47506-y · Cited by 30
Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13
Burris, B. J. D., Molina Vargas, A. M., Park, B. J., & O'Connell, M. R. (2022) · Methods · doi:10.1016/j.ymeth.2022.08.007 · Cited by 13
Guo, T., Zheng, F., Zeng, Z., Yang, Y., Li, Q., She, Q., & Han, W. (2019) · RNA Biology · doi:10.1080/15476286.2019.1642725 · Cited by 11
Metadata
- Authors
- Mohanraju, P., Makarova, K. S., Zetsche, B., Zhang, F., Koonin, E. V., & van der Oost, J.
- Venue
- Science
- Published
- 2016-08-05
- Volume
- 353
- Issue
- 6299
- Pages
- aad5147-aad5147
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2502856725
- Cited by
- 671
- References
- 165
- FWCI
- 39.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.